Radiation Plus Immunotherapy Combo Revs up Immune System to Better Attack Metastatic Melanoma, Penn Study Suggests
Perelman School of Medicine at the University of PennsylvaniaTreating metastatic melanoma with a triple threat—including radiation therapy and two immunotherapies that target the CTLA4 and PD-1 pathways—could elicit an optimal response in more patients, one that will boost the immune system’s attack on the disease, suggests a new study from a multidisciplinary team of researchers from Penn’s Abramson Cancer Center published today in Nature.